^
    4d
    Fostamatinib (R788), a spleen tyrosine kinase inhibitor, sensitizes pancreatic cancer cells to oncolytic vesicular stomatitis virus. (PubMed, Mol Ther Oncol)
    Additionally, fostamatinib inhibited PDAC cell proliferation even in the absence of viral infection, while ruxolitinib did not. Our data suggest that fostamatinib may be repurposed as an effective drug that enhances OV therapy in PDAC by promoting OV replication and suppressing tumor growth.
    Journal
    |
    SYK (Spleen tyrosine kinase)
    |
    Jakafi (ruxolitinib) • Tavalisse (fostamatinib)
    10d
    Using Fostamatinib to Treat Post-Hematopoietic Stem Cell Transplant Immune-mediated Cytopenias (clinicaltrials.gov)
    P2, N=1, Terminated, National Heart, Lung, and Blood Institute (NHLBI) | Completed --> Terminated; Clinical trial was halted prematurely due to low enrollment
    Trial termination
    |
    Tavalisse (fostamatinib)
    26d
    Inflammatory Signal Inhibitors for COVID-19 (MATIS) (clinicaltrials.gov)
    P1/2, N=185, Completed, Imperial College London | Recruiting --> Completed | N=456 --> 185
    Trial completion • Enrollment change
    |
    CRP (C-reactive protein)
    |
    Jakafi (ruxolitinib) • Tavalisse (fostamatinib)
    1m
    Network Controllability Reveals Key Mitigation Points for Tumor-Promoting Signaling in Tumor-Educated Platelets. (PubMed, Int J Mol Sci)
    A low-dose combination therapy of fostamatinib, Aducanumab, and acetylsalicylic acid (aspirin) may control TEP effects. In conclusion, our preclinical in silico approach revealed FDA-approved drugs that allow therapeutic targeting of metastasis-promoting TEPs and target NSCLC at the same time.
    Journal
    |
    SYK (Spleen tyrosine kinase) • FCGR2A (Fc fragment of IgG receptor IIa) • ITGA2B (Integrin Subunit Alpha 2b)
    |
    Tavalisse (fostamatinib) • aspirin
    1m
    Extension Study (Extended Access) of Syk-inhibition Using Fostamatinib to Treat Posttransplant Immune-mediated Cytopenias (clinicaltrials.gov)
    P2, N=0, Withdrawn, National Heart, Lung, and Blood Institute (NHLBI) | N=20 --> 0 | Trial completion date: Dec 2028 --> Nov 2025 | Enrolling by invitation --> Withdrawn | Trial primary completion date: Dec 2028 --> Nov 2025
    Enrollment change • Trial completion date • Trial withdrawal • Trial primary completion date
    |
    Tavalisse (fostamatinib)
    2ms
    Using Fostamatinib to Treat Post-Hematopoietic Stem Cell Transplant Immune-mediated Cytopenias (clinicaltrials.gov)
    P2, N=1, Completed, National Heart, Lung, and Blood Institute (NHLBI) | Recruiting --> Completed | N=20 --> 1 | Trial completion date: Apr 2026 --> Oct 2025 | Trial primary completion date: Apr 2026 --> Oct 2025
    Trial completion • Enrollment change • Trial completion date • Trial primary completion date
    |
    Tavalisse (fostamatinib)
    3ms
    2018-523-00US1: An Open-label, Dose Escalation Trial to Evaluate the Safety and Pharmacokinetics of HMPL-523 in Patients With Lymphoma (clinicaltrials.gov)
    P1, N=87, Terminated, Hutchmed | N=140 --> 87 | Trial completion date: Jan 2026 --> Mar 2025 | Active, not recruiting --> Terminated | Trial primary completion date: Dec 2024 --> Mar 2025; Study terminated by sponsor
    Enrollment change • Trial completion date • Trial termination • Trial primary completion date
    |
    sovleplenib (HMPL-523)
    3ms
    The Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of HMPL-523 in Adult Subjects With Immune Thrombocytopenia (ITP) (clinicaltrials.gov)
    P1, N=0, Withdrawn, Hutchmed | N=48 --> 0 | Recruiting --> Withdrawn
    Enrollment change • Trial withdrawal
    |
    sovleplenib (HMPL-523)
    3ms
    Study to Evaluate the Safety and Tolerability of Escalating Doses of Fostamatinib in Subjects With Stable Sickle Cell Disease (clinicaltrials.gov)
    P1, N=25, Recruiting, National Heart, Lung, and Blood Institute (NHLBI) | Trial primary completion date: Aug 2025 --> May 2026
    Trial primary completion date
    |
    Tavalisse (fostamatinib)
    3ms
    NEK9-mediated Wnt signalling repressor TLE3 rewires Docetaxel resistance in cancer cells by inducing pyroptosis. (PubMed, Br J Cancer)
    Our study demonstrated that NEK9 plays an important role in Docetaxel resistance. The novel combination of NEK9 inhibitor Fostamatinib and Docetaxel needs further clinical investigation in advanced OSCC.
    Journal
    |
    TLE3 (TLE Family Member 3, Transcriptional Corepressor)
    |
    docetaxel • Tavalisse (fostamatinib)
    5ms
    A Study on the Safety and Efficacy of TQB3473 Tablets in the Treatment of Persistent or Chronic Primary Immune Thrombocytopenia (ITP) in Adults (clinicaltrials.gov)
    P2, N=320, Not yet recruiting, Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
    New P2 trial
    6ms
    Effect of Syk Inhibitory Activity of Vialinin A on Degranulation from Antigen-Stimulated RBL-2H3 Cells. (PubMed, Biol Pharm Bull)
    Consequently, the phosphorylation of Syk downstream signalling proteins, such as linker for activation of T cells family and phospholipase Cγ1/2, essential in calcium ion mobilization and cell activation were slightly inhibited. These results suggest that vialinin A affects degranulation of RBL-2H3 cells by inhibiting Syk.
    Journal
    |
    TNFA (Tumor Necrosis Factor-Alpha) • SYK (Spleen tyrosine kinase) • USP5 (Ubiquitin Specific Peptidase 5)